8-K: Biote Corp. Investor Presentation Highlights 2025 Results

Biote Corp. released its investor presentation for April 2026, detailing 2025 financial results and providing a 2026 outlook, emphasizing growth in therapeutic wellness.

Summary

• Biote Corp. posted an investor presentation on April 3, 2026, showcasing its business and financial performance.
• The company reported 2025 revenue of $192.2 million and Adjusted EBITDA of $53.5 million, with an Adjusted EBITDA margin of 27.8%.
• As of December 31, 2025, Biote had over 9,200 Biote-Certified Practitioners and approximately 400,000 active patients.
• The presentation highlights Biote's position as a leader in hormone optimization and its expansion into broader therapeutic wellness solutions.
• Guidance for 2026 includes revenue above $190 million and Adjusted EBITDA above $38 million.
• The company repurchased approximately 5.5 million shares of its Class V voting stock for $25.1 million in 2025 and completed further repurchases in January 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, highlighting strong 2025 financial performance, a clear growth strategy in a large market, and a robust practitioner network, with reasonable 2026 guidance.

Positives

• Achieved 2025 revenue of $192.2 million.
• Generated $53.5 million in Adjusted EBITDA in 2025, with a strong margin of 27.8%.
• Maintained a network of over 9,200 Biote-Certified Practitioners.
• Serves approximately 400,000 active patients.
• The company is a recognized leader in hormone optimization with a proprietary, evidence-based platform.
• Strategic acquisition strengthens supply chain control and manufacturing efficiency.
• Share repurchase program demonstrates commitment to returning value to shareholders.
• 2026 guidance projects revenue above $190 million and Adjusted EBITDA above $38 million.

Negatives

• The company incurred restructuring costs related to a workforce reduction in 2025.
• An inventory impairment charge of $1.3 million was recognized due to a voluntary recall of select bioidentical hormone pellets.
• Executive severance costs and strategic consulting fees related to CEO transition were incurred.
• Reported a net loss of ($1) in 2025, compared to a net income of $1,597 in 2024, though this is heavily influenced by non-cash items and adjustments.

Risks

• Reliance on third parties for manufacturing of bio-identical hormones.
• Sensitivity to regulatory, economic, environmental, and competitive conditions.
• Ability to increase practitioner adoption of the Biote Method at anticipated rates.
• Significant competition within the industry.
• Potential adverse impacts from economic, business, and competitive factors, including natural disasters.
• Risks associated with expanding into existing and new markets.
• Heavy regulatory oversight in the industry.
• Changes in applicable laws or regulations and international tariffs.

Future Outlook

For 2026, Biote projects revenue to be above $190 million and Adjusted EBITDA to be above $38 million. The company aims to maximize value from top-tier providers, leverage clinical decision support software, develop differentiated offerings, intensify practitioner acquisition, and serve a broader range of physicians.

Management Comments

• "We are well-Positioned to Become the Leading Single-Source Provider of Evidence-Based Therapeutic Wellness Solutions."
• "Implementing these changes quickly, with an expectation they will take time to show results."
• "Confident in our ability to create a stronger commercial organization with increased productivity later this year."

Industry Context

StockSavvy.ai notes that Biote Corp.'s focus on hormone optimization and therapeutic wellness aligns with significant market trends, including growing consumer interest in personal health and wellness and a shift towards preventive medicine. The company's strategy to become a single-source provider of evidence-based wellness solutions positions it to capture a substantial share of this expanding market.

Comparison to Industry Standards

• The company's Adjusted EBITDA margin of 27.8% for 2025 appears strong within the health and wellness sector, though direct public comparables with identical business models are limited.
• The growth in Biote-Certified Practitioners to over 9,200 indicates successful scaling of its training and certification program, a key differentiator in the industry.
• The addressable market for hormone deficiency treatment is estimated at $7 billion+ with a 7% CAGR, suggesting significant room for growth compared to more mature healthcare segments.

Legal Proceedings

• Litigation expenses related to claims asserted by the Company's former owner were incurred.
• Other litigation expenses not related to the ongoing business were also incurred.
• Legal settlement and related expenses were recorded.

Stakeholder Impact

• Shareholders may benefit from share repurchases and potential future growth in value.
• Practitioners are supported by a proprietary platform, training, and marketing, enhancing their clinic economics.
• Patients are expected to benefit from evidence-based, individualized healthcare approaches and a broad range of wellness therapies.

Next Steps

• Maximize value from top-tier providers.
• Fully leverage enhanced clinical decision support software.
• Continue to develop high-value and differentiated offerings.
• Intensify focus on adding new practitioners.
• Accelerate growth in newly trained practitioners and optimize clinic success.
• Serve a broader range of physicians beyond early adopters.
• Drive revenue growth by strengthening accountability and improving consistency and discipline.

Key Dates

Recommendation

The filing presents a stable financial picture with clear strategic direction and growth potential in the therapeutic wellness market. While positives like strong Adjusted EBITDA margins and a growing practitioner base are evident, the company also faces risks and has incurred restructuring costs. The 2026 guidance is positive but not exceptionally aggressive. Therefore, a 'hold' recommendation is appropriate pending further operational execution and market developments.

Keywords

Hormone Optimization, Therapeutic Wellness, Biote Method, Investor Presentation, Adjusted EBITDA, Practitioner Training, Dietary Supplements, Biote Corp.